Clinical Trial Update: Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction [Phase 2]

View source ↗

Summary

Phase II, prospective, single-arm trial evaluating irinotecan liposome injection with platinum, immune checkpoint inhibitors, and anlotinib for maintenance ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Immune checkpoint inhibitor (unspecified)
• Irinotecan hydrochloride liposome injection (Onivyde) (irinotecan liposome injection)
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: China Medical University, China | Conditions: Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING